Literature DB >> 5337167

Chloroquine: mechanism of action.

W M Sams.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 5337167

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  8 in total

1.  Remarkable recovery of a steroid-responsive recurrent polyneuropathy.

Authors:  D C DeVivo; W K Engel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-02       Impact factor: 10.154

Review 2.  [Biochemistry of some parasitic helminths and protozoa and the mode of action of some antiparasitic drugs].

Authors:  H Metzger
Journal:  Z Parasitenkd       Date:  1970

3.  Action of chloroquine phosphate in rheumatoid arthritis. 1. Immunosuppressive effect.

Authors:  G S Panayi; W A Neill; J J Duthie; J N McCormick
Journal:  Ann Rheum Dis       Date:  1973-07       Impact factor: 19.103

4.  Action of chloroquine phosphate in rheumatoid arthritis. II. Chromosome damaging effect.

Authors:  W A Neill; G S Panayi; J J Duthie; R J Prescott
Journal:  Ann Rheum Dis       Date:  1973-11       Impact factor: 19.103

5.  Augmentation of pentagastrin stimulated gastric secretion in the Heidenhain pouch dog by amodiaquine: inhibition of histamine methyltransferase in vivo?

Authors:  H Troidl; W Lorenz; H Barth; H Rohde; G Feifel; A Schmal; K Goecke; A Reimann-Huhnd; W Seidel
Journal:  Agents Actions       Date:  1973-10

6.  Effect of chloroquine on the PHA-induced lymphocyte transformation.

Authors:  T Ruzicka; H Loosen; D Strassburger; G Goerz
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

7.  Inhibition of protein phosphorylation by chloroquine.

Authors:  H Kalisz; G Pohlig; H Holzer
Journal:  Arch Microbiol       Date:  1987-04       Impact factor: 2.552

Review 8.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.